Angela Harris-Bonner, APRN
Psychiatric/Mental Health · Petersburg, VANPI 1134566334
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,830 of the $11,238 with a category attached, or 60.8%. 9 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 43.4% of the total. 2025 is the largest year on record at $7,038, 4.5 times the $1,578 reported in 2023. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $48.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$686
- Otsuka America Pharmaceutical, Inc.$551
- plus $786 from 3 others
What the payments were for
- Consulting fees$3,00027%
- Travel & lodging$1,17610%
- Food & beverage$6,83061%
- Education$2322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 23 | $4,876 |
| AbbVie | 89 | $2,080 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $1,167 |
| Teva Pharmaceuticals USA, Inc. | 57 | $1,093 |
| Neurocrine Biosciences, Inc. | 9 | $686 |
| Otsuka America Pharmaceutical, Inc. | 7 | $551 |
| Johnson & Johnson | 8 | $464 |
| Axsome Therapeutics, Inc. | 3 | $177 |
| Alkermes, Inc. | 2 | $144 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$705
- INGREZZA$602
- ARISTADA$486
- VRAYLAR$485
- INVEGA$382
- UZEDY$366
- ABILIFY MAINTENA$245
- COBENFY$137
- Austedo XR$125
- NUEDEXTA$125
- REXULTI$125
- ARISTADA INITIO$122
- Auvelity$121
- ABILIFY ASIMTUFII$120
How this compares
$11,238 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 166 | $405,687 |
| IngrezzaValbenazine Tosylate | 31 | $265,598 |
| Invega TrinzaPaliperidone Palmitate | 13 | $127,751 |
| Austedo XrDeutetrabenazine | 14 | $111,943 |
| Abilify MaintenaAripiprazole | 24 | $66,304 |
| UzedyRisperidone | 27 | $55,207 |
| CaplytaLumateperone Tosylate | 20 | $32,035 |
| Aripiprazole | 158 | $14,504 |
| Lurasidone Hcl | 47 | $10,547 |
| Risperdal ConstaRisperidone Microspheres | 12 | $7,641 |
| Clozapine | 69 | $6,710 |
| Haloperidol Decanoate | 134 | $6,366 |
| Haloperidol | 183 | $5,534 |
| Fluphenazine Decanoate | 47 | $4,708 |
| Paliperidone ErPaliperidone | 15 | $4,138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $464 | $541,079191 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $686 | $265,59831 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $1,093 | $167,15041 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $551 | $66,30424 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,167 | $32,03520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Petersburg
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
- Pamela RuppelRoanoke$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.